Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
LDR-R5255 | Rabbit | Rabbit LDL R Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
LDR-H82E7 | Human | Biotinylated Human LDL R Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
LDR-C5222 | Cynomolgus | Cynomolgus LDL R Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
LDR-H5254 | Human | Human LDL R Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
LDR-M52H8 | Mouse | Mouse LDL R Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
LDR-H5224 | Human | Human LDL R Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Cynomolgus LDL R, His Tag (Cat. No. LDR-C5222) with an affinity constant of 1.24 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CP-230821 | CP-230821 | Preclinical | Pfizer | Atherosclerosis, Hypercholesterolemia | Details |
Phosphorylcholine monoclonal antibody | PC-mAb | Phase Ⅱ | Dyax Pharma, Athera | Cardiovascular disorders, Atherosclerosis | Details |
ANG-2008 (AngioChem) | ANG-2008,ANG 2008,ANG2008 | Preclinical | AngioChem | Parkinson's disease (PD) | Details |
Axitirome | CGP-26214; CGS-26214; CGP 26214; CGS 26214 | Phase Ⅰ | Novartis | Hyperlipidemia | Details |
Serpin Peptide 16 | SP-16,SP16 | Phase Ⅱ | Serpin Pharma | Inflammation, Myocardial infarction (MI) | Details |
LLG-783 (Novartis) | LLG-783 | Phase Ⅱ | Novartis | Intermittent claudication, Peripheral arterial disease (PAD) | Details |
CVI-LM001 | C-8304; CVI-LM001 | Phase Ⅱ | CVI Pharmaceuticals | Hyperlipidemia | Details |
Paclitaxel trevatide | ANG-1005; GRN-1005; SNG-1005 | Phase Ⅲ | AngioChem, Xinogen Pharma | Glioma, Breast cancer, Glioblastoma, Brain metastases | Details |
This web search service is supported by Google Inc.